Notably, the consensus molecular subtype 3 (CMS3) of CRC, which is enriched for KRAS mutations, is characterized by profound alterations in multiple metabolic signatures, including Gln metabolism (14). This evidence concerns the gene KRAS and colorectal carcinoma.